Amphastar pharmaceuticals reports financial results for the three months ended march 31, 2025

Reports net revenues of $170.5 million for the three months ended march 31, 2025 rancho cucamonga, ca / access newswire / may 7, 2025 / amphastar pharmaceuticals, inc. (nasdaq:amph) ("amphastar" or the "company") today reported results for the three months ended march 31, 2025. first quarter highlights net revenues of $170.5 million for the first quarter gaap net income of $25.3 million, or $0.51 per share, for the first quarter adjusted non-gaap net income of $36.9 million, or $0.74 per share, for the first quarter dr. jack zhang, amphastar's president and chief executive officer, commented: "we are confident in the potential of our portfolio, particularly with the growth of baqsimi® and primatene mist®, and the promising pipeline of biosimilars and proprietary products.
AMPH Ratings Summary
AMPH Quant Ranking